Importantly, these medications do not replace statin therapy in patients requiring lipid-lowering treatment but may provide complementary benefits in comprehensive cardiovascular risk management
Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1
Plans include a mix of housing options both for sale and for rent green spaces, retail, health and wellness, and amenities that serve the community and invite people in
The Bottom Line Snacking on GLP-1 medications is a tool, not a requirement
These medications were originally developed for type 2 diabetes management but have demonstrated substantial weight loss effects in clinical trials and real-world use
As of 2024, over 2% of Americans use GLP-1s for overweight/obesity, and around 4% use them overall (for any indication), with nearly half of users using them for weight loss